http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2248624-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2002-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4154971f3ad9d38c0944e0e917c007ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_810d4622159ea89d8eb3fdef3203c97a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_296913dd0761cf02f3f3994a76c9a243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcad364f39c006699fa2498f8f74bc70 |
| publicationDate | 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2248624-T3 |
| titleOfInvention | PURISIMAL ORAL FORMULATION OF FLUDARA WITH FAST RELEASE OF ACTIVE SUBSTANCE. |
| abstract | Formulation of tablets with rapid release, which comprises 1 to 100 mg of the active substance will flow in a purity of> 99, 19%, in common with lactose monohydrate, colloidal silicon dioxide, microcrystalline cellulose (Avicel), croscaramellose- Na (sodium carboxymethylcellulose) and magnesium stearate, characterized in that the impurities in the fludara do not exceed percentages as follows: 0.02% of 2-fluoro-9- (â-D-arabino-furanosyl) -9H-purin- 6-amine, 0.12% of 6-amino-9- (5-O-phosphono-â-D-arabino-furanosyl) -9H-purin-2-ol, 0.02% of 2-fluoro-9H- purin-6-amine, 0.02% of 6-amino-9H-purin-2-ol, 0.05% of 2-fluoro-9- (5-O-phosphono-â-D-ribofuranosyl) - 9H- purin-6-amine, 0.1% of 9- (3, 5-O-diphosphono-â-D-arabino-furanosyl) - 2-fluoro-9H-purin-6-amine, 0.1% of 9- (2, 5-O-diphosphone-â-D-arabino-furanosyl) - 2-fluoro-9H-purin-6-amine, 0.02% of 2-fluoro-9- (5-O-phosphono-â- D-arabino-furanosyl) -9H-purin-6-amine, 0.06% of 2-ethoxy-9- (5-O-phosphono-â-D-arabino-furanosil ) -9H-purin-6-amine, 0.02% of 2- (6-amino-9H-purin-2-yl) -9- (5-O-phosphono- â-D-arabino-furanosyl) -9H -purin-6-amine and O, O '' - bis [2- (6-amino-2-fluoro-9H-purin-9-yl) - 5-deoxy-á-D-arabino-furans-5-yl ] - phosphate, 0.1% of 9- (2-chloro-2-deoxy-5-phosphono-â-D-arabino-furanosyl) -2-fluoro-9H-purin-6-amine and 0.1% of 9- (2,5-anhydro-â-D-arabino-furanosyl) -2-fluoro-9H-purin-6-amine. |
| priorityDate | 2001-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.